Hydrocodone–Trazodone Drug Interaction in Adults and Older Adults With Chronic Pain
Concomitant hydrocodone and trazodone can increase the risk of serotonin syndrome and central nervous system (CNS) depression. (dailymed.nlm.nih.gov)
In older adults, the risk of clinically significant sedation and respiratory depression is generally higher with opioid-containing regimens. (medlineplus.gov)
Pharmacologic Interaction Mechanisms
Hydrocodone labeling for serotonergic drug combinations reports serotonin syndrome as a class interaction with opioids when used with other drugs that affect the serotonergic neurotransmitter system, including trazodone. (dailymed.nlm.nih.gov)
Trazodone labeling reports increased serotonin syndrome risk with concomitant serotonergic agents and lists relevant serotonergic drug combinations and monitoring. (dailymed.nlm.nih.gov)
Trazodone labeling also states that trazodone may enhance the response to CNS depressants. (dailymed.nlm.nih.gov)
Clinical Risk: Serotonin Syndrome
Serotonin syndrome is described by trazodone labeling as involving mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. (dailymed.nlm.nih.gov)
Opioid product labeling for hydrocodone and related opioid products includes trazodone among drugs that affect serotonin neurotransmission in the context of reported serotonin syndrome. (dailymed.nlm.nih.gov)
If serotonin syndrome is suspected, hydrocodone labeling recommends discontinuation and evaluation for serotonin syndrome. (dailymed.nlm.nih.gov)
Clinical Risk: Sedation and Respiratory Depression
Hydrocodone labeling includes warnings for life-threatening breathing problems and notes the greatest risk with treatment initiation and dose increases. (medlineplus.gov)
Opioid product labeling for serotonergic and CNS-depressant risks describes additive CNS/respiratory depression concerns with concomitant CNS depressants. (fda.gov)
Trazodone labeling notes enhanced effects of CNS depressants when combined with other CNS-depressant agents. (dailymed.nlm.nih.gov)
Population Considerations for Older Adults
Trazodone labeling includes orthostatic hypotension and syncope warnings, which can worsen fall risk in older adults who also receive opioids with sedating effects. (dailymed.nlm.nih.gov)
Opioid adverse effects related to sedation and breathing risk are particularly important during opioid initiation and titration in older adults. (medlineplus.gov)
Practical Monitoring and Action Thresholds
Monitoring is recommended for signs and symptoms of serotonin syndrome during concomitant use and particularly during initiation or dose adjustment. (dailymed.nlm.nih.gov)
Serotonin syndrome alarm features that warrant urgent evaluation include agitation or hallucinations, autonomic instability (e.g., diaphoresis or hyperthermia), neuromuscular abnormalities (e.g., tremor, hyperreflexia), and seizures. (dailymed.nlm.nih.gov)
Monitoring is recommended for opioid-related respiratory depression and profound sedation, including during initiation and dose increases. (medlineplus.gov)
Consideration for naloxone availability may be appropriate when opioid therapy is used with additional CNS depressant risks, consistent with opioid labeling warnings for overdose preparedness. (fda.gov)
Overall Clinical Use Assessment
This combination is clinically plausible in adults, but it requires careful assessment of serotonergic risk and additive sedation/respiratory-depression risk. (dailymed.nlm.nih.gov)
When both medications are used together, close follow-up during initiation and dose changes is specifically relevant because both serotonin syndrome risk and opioid respiratory depression risk are emphasized in labeling. (dailymed.nlm.nih.gov)
Medication Reconciliation Items for Chronic Pain With Possible Depression or Insomnia
Medication reconciliation should determine whether any other serotonergic agents are present (for example SSRIs/SNRIs, tramadol, or MAOIs), since trazodone labeling and opioid labeling both emphasize higher serotonin syndrome risk with other serotonergic drugs. (dailymed.nlm.nih.gov)
Medication reconciliation should identify other CNS depressants (for example benzodiazepines, sedative-hypnotics, alcohol) because opioid labeling warns about additive CNS/respiratory depression with CNS depressants. (fda.gov)
Medication reconciliation should screen for conditions associated with opioid breathing risk and for factors that increase vulnerability to adverse CNS effects in older adults. (medlineplus.gov)